antibody

FEL D1 Major Allergen I Polypeptide Chain 1 Antibody Affinity Purified C-epitope

MBS540402

0.1 mg

390 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, immunoprecipitation, enzyme immunoassay

Antibody

FEL D1 Major Allergen I Polypeptide Chain 1 Antibody Affinity Purified C-epitope

[FEL D1]

[CH1, Fel D1, AG4, Allergen Cat-1, Allergen D I-A, Allergen FDI, Allergen Fel Di, Allregen: Fel d 1-A]

[Major allergen I polypeptide chain 1; Major allergen I polypeptide chain 1; major allergen I polypeptide chain 1; AG4; Allergen Cat-1; Allergen Fel d I-A; Allergen FdI; Allergen Fel dI; Allergen: Fel d 1-A]

[FEL D1]

[LOC677877; CH1; CH1; Allergen FdI; Allergen Fel dI]

FEL1A_FELCA

Polyclonal

Rabbit

Cat

92

Affinity Purified Immunoglobulins

Store at -20°C for long term storage.

ELISA (EIA), Immunoprecipitation (IP), Western Blot (WB)

Dot Blot: 1:10,000. ELISA: 1:10,000. Immunoprecipitation: 1:200 . Western Blot: 1:500

Western Blot (WB)

Immunogen: Synthetic peptide taken within amino acid region 42-88 on feline Major Cat Allergen I polypeptide chain 1. Immunoglobulin & Concentration: 0.72 mg/ml IgG in antibody stabilization buffer.

Determinant: C-epitope

Primary Antibodies; Immunology; FEL D1 Major allergen 1 polypeptide chain 1 Antibody

A number of house pet bourn allergens have been studied for allergic reactions in general population. Domestic cat (Felis domestica) is an important source of indoor allergen Fel D'1 that affects a large opulation. Fel D1 is also established to cause catinduce asthma in sensitive patients. The levels of Fel Dl nd Can F1 were high in homes of former pet-owners compared to the homes without pets. Children with ild allergy to animal dander may have profound increase in bronchial sensitivity (increased sputum osinophil peroxidase (EPO) and myeloperoxidase (MPO) activity as a result of constant exposure of nimal allergens (Fel Dl and Can F1) at public places. Allergic reactions to Fel D1 are effectively reduced y conventional immunotherapy in many patients, but this type of immunotherapy has severe reactions, ncluding anaphylaxis and requires several years cf injections for successful desensitization. Several trategies have been employed to address these issues including use of cat allergen peptides, chimeric onstructs of Fel D1 and Fc portion of human lgEs (1). The synthetic cat allergen peptides lack the tertiary tructure of nattve Fel Dl and posses reduced capacity to bind Fel D1-specific lgE. These peptides when iven to patients sensitive to cat allergens showed improvement in pulmonary function and tolerance to ats (1). The exposure of chimeric human -cat fusion protein composed of truncated human gGFcgamma'1 and the Fel D1 . The chimeric protein induces dose dependent inhibition of Fel D'l-driven gE mediated histamine release form cat allergic donors (2). The allergen is a 38 kDa dimer composed of wo 19 kDa subunits. Each 19 kDa subunit comprises two disulfide linked polypeptide chains, a light lpha-chain and a heavy beta-chain containing an N-linked oligosaccharide. The alpha light chain and the eavy betachain are linked in an anti-parallel configuration. The Fel D'1 glycosylation at Asn 33 is of eterogeneous triantennary structure caused by terminal sialic acid and fructose residues attached to beta-alactose residues. MBS has developed anti-Fel D1-selective antibodies against 3 epitopes covering he majority of the protein. The affinity purified mono-specific polyclonal antibodies to FEL D1 strongly abels a 15-18 kDa protein in cat saliva samples examined. MBS employs cyclic peptide ethodology for generating antibodies, which results in higher titer and specificity. Western blotpositive ontrol in readyto-use SDS-sample buffer (PC-FELD1) and antigenic blocking peptide (P-FELDl .3) are vailable. Antibodies can be conjugated with fluorescent probes or other secondary enzymes upon request t extra charge.

1169665

P30438.2

P30438

0.1 mg

390 USD